drugset / Trial / NCT00436449
RN1001(Avotermin) in Scar Improvement Following Breast Augmentation
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This will be a multi-centre, double-blind, within-subject, placebo controlled randomised trial in female subjects. All subjects will undergo bilateral breast augmentation surgery. Immediately following surgery, each subject will receive 100µl containing 50ng or 200ng of RN1001 per linear centimetre intradermally into both margins of one breast wound, and 100µl of placebo solution per linear centimetre intradermally into both margins of their other breast wound. The allocation of treatment to wound (left or right) will be randomised and double blind.
Timeline
- Start
- 2004-12
- Primary completion
- 2007-10
- Completion
- 2008-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avotermin | Protein / enzyme biologic | 50 ng | Other |
| Subject | Avotermin | Protein / enzyme biologic | 200 ng | Other |
Indications
No indication recorded.